You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories
Contributor:
Lieberman, Joshua A.;
Pepper, Gregory;
Naccache, Samia N.;
Huang, Meei-Li;
Jerome, Keith R.;
Greninger, Alexander L.
imprint:
American Society for Microbiology, 2020
Published in:Journal of Clinical Microbiology
Language:
English
DOI:
10.1128/jcm.00821-20
ISSN:
0095-1137;
1098-660X
Origination:
Footnote:
Description:
<jats:p>Multiple laboratory-developed tests (LDTs) and commercially available assays have emerged to meet diagnostic needs related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. To date, there is limited comparison data for these different testing platforms. We compared the analytical performance of a LDT developed in our clinical laboratory based on CDC primer sets and four commercially available, FDA emergency use authorized assays for SARS-CoV-2 (Cepheid, DiaSorin, Hologic Panther, and Roche Cobas) on a total of 169 nasopharyngeal swabs.</jats:p>